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Changes in Physician Knowledge, Attitudes, Beliefs,
and Practices regarding Lung Cancer Screening
To the Editor:
More patients die of lung cancer than breast, colorectal, and
prostate cancers combined (1). After the National Lung
Screening Trial finding of a 20% relative reduction in mortality of
lung cancer with lung cancer screening (LCS) by low-dose
computed tomography (LDCT) (2), the U.S. Preventive Services
Task Force published recommendations for LCS in high-risk
patients (current and former heavy smokers aged 55–80 yr)
annually with LDCT (3).
Eligibility for LCS is based on age, pack-years of smoking
history, and years since quitting, with reimbursement
dependent on physician and patient engagement in shared
decision making (SDM). Rates of LCS from 2013 to 2016 were
low, ranging from 2% to 7% (4, 5). To understand reasons for low
LCS rates, several studies have examined physician attitudes
and beliefs regarding screening (6–14). However, these studies
were cross-sectional and conducted at a single time point.
Isolated snapshots may not accurately reflect provider changes in
LCS attitudes and practices. To assess changes in physicians’
knowledge, attitudes, and practice patterns regarding LCS
over time, we redeployed our 2015 LCS physician opinion
survey (6, 15) in 2018 to compare two cross-sectional cohorts
of physicians.
Methods
Using the Tailored Design Method, we conducted a Qualtrics
survey of physicians in family medicine, internal medicine, and
pulmonary medicine at a large academic medical center in the
spring of 2015 and in the spring of 2018 (16). We included 23
survey items focused on LCS opinions, knowledge, practices, and
perceived barriers. Physicians’ LCS opinions were evaluated using a
5-point Likert scale that ranged from strongly agree to strongly
disagree. Physicians were asked to rank their opinions on six
statements (Figure 1). Physician practice pattern survey questions
asked about behaviors in the prior 12 months with response options
of yes, no, or don’t recall (Figure 2) and a single question about
referrals for smoking cessation programs. To ascertain physicians’
perceived barriers to LCS, we provided a list of potential barriers
(Figure 3) and asked physicians to select all perceived barriers.
We identified physicians through online academic directories
and made seven points of contact per the Tailored Design
Methodology. Consent was determined by return of the survey.
Participating physicians were incentivized with the opportunity to
enter into a random drawing for an iPad. This study was approved
by the University of North Carolina at Chapel Hill Institutional
Review Board (approval no. 13-2672).
Between the two surveys, we implemented a quality
improvement project to address key processes required for high-
quality LCS implementation (17, 18) and disseminated LCS
resources to physicians. We conducted outreach to primary care
providers in outpatient clinics, providing written educational
materials pertaining to LCS and tobacco treatment as well as
demonstrating web-based SDM tools.
We compared responses from physicians in 2015 with those in
2018 using t tests for continuous outcomes and chi-square or
Fisher’s exact tests for categorical outcomes. We accounted for
multiple comparisons by adjusting all P values using the false
discovery rate method (19).
Results
Survey response rates were 40.5% (89 of 220) in 2015 and 30.0% (73
of 243) in 2018. There were no differences in the distribution of
age, sex, race, years in clinical practice, or proportion of time spent
in outpatient care or in the average number of outpatients seen per
week for respondents in 2015 versus 2018. The proportions of
respondents in family medicine were 41.6% in 2015 and 43.8% in
2018; in internal medicine, they were 39.5% in 2015 and 39.3% in
2018; and in pulmonary medicine, they were 19.1% in 2015 and
16.4% in 2018. Over time, there was an increase in the proportion of
physicians who reported LCS as beneficial (47.7% vs. 77.2%;
adjusted P, 0.01) (Figure 1). In both years, approximately half of
respondents were undecided on the cost effectiveness of LCS
(56.3% and 48.6%, respectively; adjusted P= 0.09), and most of the
respondents believed they had enough knowledge to explain the
pros and cons of LCS (64.7% in 2015 and 75.7% in 2018; adjusted
P= 0.49). Approximately two-thirds of physicians cited time
restrictions during the patient’s clinic visit and other problems
having higher priority than LCS (62.3% in 2015 and 70.0% in 2018;
adjusted P= 0.49).
Over the 3 years between 2015 and 2018, the proportion of
physicians who reported initiating LCS discussions increased from
45.9% to 87.3% (adjusted P= 0.03), and the proportion who
reported ordering an LCS examination more than doubled (from
32.2% to 74.6%; adjusted P= 0.02) (Figure 2). The proportion of
physicians who referred a patient to another provider for LCS
evaluation also increased (12.9% in 2015 vs. 29.9% in 2018; adjusted
P= 0.03).
The proportion of physicians who reported any barrier to
LCS was similar: 89.9% in 2015 and 86.3% in 2018 (Figure 3).
Although many physician-reported barriers to LCS remained constant
over time, fewer physicians reported lack of evidence (adjustedP=0.05)
or patient cost (adjusted P=0.03) as a barrier in 2018 than in 2015.
Discussion
We found significant increases between 2015 and 2018 in the
proportion of physicians who reported initiating a discussion about
LCS, ordering LDCT for LCS, discussing LDCT results, and
referring patients for further evaluation. In contrast, physicians
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reported a similar proportion of patients asking about LCS,
suggesting that physicians have gained knowledge and experience
in LCS, whereas patients’ knowledge regarding LCS has not
changed. This is an area for future investigation.
According to physician respondents, barriers to LCS
remain a concern, with few barriers decreasing over time.
Other studies reported similar barriers at a single time point (9, 10,
12, 13, 20–22). Because of the complexities of LCS, physicians
find it increasingly challenging to allocate their already
limited time and resources to incorporate the necessary
and required components of LCS (patient eligibility assessment,
benefit and risk discussion coupled with SDM, and
discussion/referral/treatment for tobacco addiction) into
daily practice. To accomplish widespread acceptance of
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Figure 1. (A–F ) Comparison of physicians’ lung cancer screening opinion statements from 2015 and 2018.
1066 AnnalsATS Volume 16 Number 8| August 2019
LETTERS
 
Our survey was implemented using the Tailored Design
Method, a standard survey methodology that is rigorous in
terms of survey design and deployment. Our response rates are
similar to those for other nonspecialty physician surveys focused
on LCS (range from 7% to 53% [7, 9, 11, 13, 20, 22, 25]), although
our sample sizes are modest. It is possible that attitudes and
practice patterns at our single site may not represent national
patterns.
We found that physicians view LCS as more beneficial and
were more likely to order LDCT for LCS in 2018 than in 2015;
however, physicians continued to have concerns regarding time
restrictions and other barriers to LCS. This research has implications
for continued adoption and dissemination of LCS into practice. As LCS
continues to gain momentum in the United States and with
preliminary results of the Nelson Lung Cancer Screening Trial favoring
LCS (26), identifying and addressing barriers to LCS are needed.
Author disclosures are available with the text of this letter at
www.atsjournals.org.
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Influence of County Sampling on Past Estimates of
Latent Tuberculosis Infection Prevalence
To the Editor:
The National Health and Nutrition Examination Survey
(NHANES) has tested for Mycobacterium tuberculosis infection
three times: in 1971–1972, 1999–2000, and 2011–2012. Based on
tuberculin skin test results, the estimated national prevalence of
latent tuberculosis infection (LTBI) among adults was 11–18% in
1971–1972 but has remained less than or equal to 6% in
subsequent NHANES cycles (1–4). A single 2-year NHANES
cycle is designed to produce accurate and stable estimates for
conditions with at least 10% prevalence in the noninstitutionalized
civilian U.S. population (5–7), suggesting that NHANES might
no longer be as nationally representative for LTBI as it is for
more common health conditions. Approximately 30 counties
were selected for each 2-year cycle (5). We wished to examine
whether persons in selected counties might have been
systematically more or less likely to have a positive
tuberculin skin test result than their counterparts in the
approximately 3,100 counties that were not selected for
NHANES participation.
Methods
We created a non-NHANES dataset with demographic profiles
and tuberculosis data for all 3,143 U.S. county equivalents
(Table 1). The U.S. Census Bureau and Department of
Agriculture websites provided each county’s population
size and racial/ethnic composition, rural versus urban
classification, and poverty prevalence for 1970 through 2013.
The National Tuberculosis Surveillance System provided annual
tuberculosis disease incidence, with the U.S. Census Bureau’s
Current Population Survey providing county population
denominators.
We also used genotyping results to derive an estimate of
LTBI prevalence for each county. Briefly, this simple back-
calculation method assumed that tuberculosis cases not
attributed to recent transmission (i.e., based on genotyping
results) instead arose from preexisting LTBI. Then a 0.1%
annual risk of reactivation was used to derive an estimated
number of county residents with untreated longstanding LTBI
(8). This county-level LTBI estimation method has not been
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